PARP1 and esophageal squamous cell carcinoma: Antisense oligonucleotides or siRNA therapeutics targeting PARylator, or small molecules that disrupt the PARylator-PARP1 interaction, could be explored as potential radiosensitizers or chemo-potentiators in ESCC [41–44].